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Rogelio García-Centeno8, Javier Caneiro-Gómez3, Ihab Abdulkader3, Roberto González-
Amaro9,10 & Mónica Marazuela1
The immune checkpoint based therapy targeting the programmed death-1 (PD-1) receptor and its 
PD-L1 ligand has recently been approved for the therapy of different malignant conditions, but not 
yet for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this context, we evaluated 
the expression of PD-1 and PD-L1 in GEP-NETs and its potential correlations with clinical outcomes. 
Expression of PD-1/PD-L1 was analyzed by immunohistochemistry in 116 GEP-NETs and 48 samples 
of peritumoral tissue. In addition, the expression of these molecules was assessed by flow cytometry 
in peripheral blood mononuclear cells (PBMC) from patients with GEP-NETs (n = 32) and healthy 
controls (n = 32) and in intratumoral mononuclear cells (TMCs) (n = 3). Expression of PD-L1 and PD-1 
was detected by immunohistochemistry in 6% and 1% of tumor tissue samples, respectively, and in 
8% of peritumoral tissue samples, for both markers. We also observed that PD-1 expression by TMCs 
was associated with metastatic disease at diagnosis, and the levels of circulating PD-1+ PBMCs were 
associated with progressive disease upon follow-ups. In addition, circulating PD-1+ PBMCs were 
significantly correlated with PD-L1 expression by tumor cells. Our data suggest that PD-1/PD-L1 
is expressed in 1 to 8% of GEP-NETs, and that this feature is significantly associated with disease 
evolution (p < 0.01).
Different malignant cells may express molecules that are able to induce an immune response, which may be able 
to eliminate these tumor cells or interfere with tumor progression and metastases. However, malignant cells may 
also express different molecules that are able to block or interfere with the activation and proliferation of immune 
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cells, avoiding thus the different mechanisms of tumor destruction by the immune response1. In this regard, 
several receptor/ligand systems (immune checkpoints) that are able to downregulate the immune activation have 
been characterized, including the CTLA-4/CD80, CD86 and PD-1/PD-L1, PD-L2 molecular systems2. Thus, it 
has been widely described that the interaction of the CTLA-4 or PD-1 membrane receptors with their ligands 
induce different intracellular signal pathways that inhibit the activation of immune cells, mainly T lymphocytes3. 
Accordingly, the blockade of interaction between CTLA-4 and CD80/CD86 or PD-1 with PD-L1/PD-L2 is able 
to increase the immune response against tumor cells, exerting thus a significant therapeutic effect4. However, 
although the so called immune checkpoint based therapy with PD-1/PD-L1 blocking agents is useful in a signif-
icant proportion of patients with different cancer types5–8, many of them are refractory to this type of treatment9.
PD-1 is a membrane receptor that under steady state conditions is mainly expressed by a small proportion of 
conventional T cells and by most T regulatory lymphocytes10. However, upon activation (through the T cell recep-
tor or different cytokine receptors, mainly those for IL-2, IL-15 and IL-10), most CD4+ and CD8+ conventional 
T cells show PD-1 expression11. Likewise, it has been described that other immune cell types such as monocytes, 
macrophages, B lymphocytes or antigen presenting dendritic cells (DC’s) are able to express PD-111.
Two PD-1 ligands have been described, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), which show 
similar effects but different patterns of expression12,13. Thus, PD-L1 is a cell membrane anchored molecule that 
is detected in a significant fraction of unstimulated conventional T cells and most T regulatory (Treg) lympho-
cytes10. In addition, the expression of PD-L1 can be induced in B cells, monocytes and myeloid and plasmacytoid 
DC’s14–17. Furthermore, PD-L1 expression can be detected in other non-immune cells (for example, vascular 
endothelium), including tumor cells18. In contrast, PD-L2 expression is restricted to some immune activated cell 
types, mainly B lymphocytes, DC’s and monocytes10.
The immune regulatory function of PD-1 receptor has been extensively analyzed. Thus, it has been described 
that upon interaction with any of their ligands, different intracellular signals are generated, which inhibit the acti-
vation pathways induced through the TCR and CD28 in T lymphocytes and through other stimulatory receptors 
in different immune cell types19. According to this, upon PD-1 engagement it is inhibited the activation, prolif-
eration and surveillance of conventional T cells11. Conversely, PD-1 is involved in the generation and function 
of Treg lymphocytes20. Therefore, the blockade of PD-1 or their ligands results in an increased reactivity of the 
immune system, in vitro and in vivo, in animal models and humans21. Accordingly, different genetic polymor-
phisms of the PD-1 gene (PDCD1) have been associated with autoimmune disease, including type-1 diabetes 
mellitus and systemic lupus erythematosus22,23.
Neuroendocrine tumors (NETs) consist of a heterogeneous group of uncommon neoplasms derived from 
enterochromaffin epithelial cells. These cells have many functional and structural similarities with normal endo-
crine cells, including production of hormones and peptides like chromogranin A and synaptophysin, which can 
cause characteristic hormonal syndromes24. These neoplasms include the gastroenteropancreatic neuroendo-
crine tumors (GEP-NETs), which the primary lesions are usually localized in the gastric mucosa, small and large 
intestine, rectum, or pancreas. GEP-NETs account for approximately 70% of all NETs25. Although GEP-NETs 
are increasingly being diagnosed, a concomitant improvement in outcomes has not been noted. Unlike other 
malignancies, the natural history of NETs is difficult to predict and most well-differentiated GEP-NETs show an 
indolent course, even if metastases are present, whereas others may progress rapidly with median survival dura-
tion ranging from 5 to 56 months26. Although the first therapeutic option for GEP-NETs is the surgical removal 
of malignant tissue, complete cure is not possible in many cases. Thus, the characterization of biomarkers of 
prognosis and therapeutic response is an important issue in this condition. Therefore, we decided to assess the 
expression of the PD-1 receptor and its main ligand (PD-L1) in GEP-NETs as well as to evaluate its possible rela-
tionship with clinical outcome. We found that PD-1 expression is detected in a small but significant proportion 
of GEP-NETs and that the presence of this receptor is significantly associated to increased malignancy. Our data 
suggest that immune checkpoint based therapy with PD-1 blockade could be useful in significant fraction of 
patients with GEP-NETs.
Results
PD-L1 expression in GEP-NETs. First, we analyzed the expression of PD-L1 by IHC in tumor and peri-
tumoral tissue samples. As shown in Fig. 1, PD-L1 expression using the clone SP142 was found in 7 of the 116 
GEP-NET tumor samples (6.1%) and in 4 of the 48 samples of peritumoral tissue (8.3%). No immunoreaction was 
detected with the other antibodies (clones 28-8 and 22C3). PD-L1 staining in tumor cells was mainly observed 
in cell membrane (Fig. 1a). Some infiltrating cells located at the interface between neoplastic cells and stroma 
showed faint to moderate PD-L1 staining (Fig. 1e). These PD-L1+ cells included CD163+ or CD68+ mac-
rophages (Fig. 1b,f,j–l) but not CD3+ T lymphocytes (Fig. 1c,g,m–o). In some cases, infiltrating cells also showed 
PD-1 staining (Fig. 1h).
Characterization of the immune cell infiltrate in GEP-NETs. We then characterized the tumor 
immune cell infiltrate by using IHC and immunofluorescence. CD3+ T cells were detected in both the per-
itumoral tissue and between the tumor cells with a CD3 median IHC score of 4 in both groups (Fig. 2a,e; 
hematoxylin-eosin staining Fig. 2d), whereas FOXP3 expression, a characteristic of Treg cells, was found in 20.5% 
of peritumoral samples analyzed (Fig. 2b) and in 13.6% of tumor samples (Fig. 2f). There was no significant dif-
ference in CD3 or FOXP3 expression score between tumor and peritumoral tissue (p > 0.05). In contrast, PD-1 
expression was observed in 8.3% of peritumoral samples and in only 0.9% of tumor tissue (p < 0.05, Fisher exact 
test, Fig. 2c and g). Furthermore, immunofluorescence microscopy analysis revealed the co-expression of CD3 
and PD-1 and CD3 and FOXP3 in the peritumoral tissue (Fig. 2h,i). However, less than 5% cells co-expressed 
CD3, FOXP3 and PD-1 (Fig. 2j,k).
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Expression of PD-1 is associated to increased malignancy in patients with GEP-NETs. Next, 
we analyzed the possible relationship between PD-1/PD-L1 expression and malignancy features (Table 1). There 
was no difference in the immunostaining for CD3 (median IHC score of 4 in both groups, p > 0.05, Fig. 3a), 
FOXP3 (positive staining in 13.8% and 15.7%, respectively, Fig. 3b) and PD-L1 (positive staining in 6.0% and 
6.7%, respectively, Fig. 3d) in tumors from patients with metastatic disease compared to tumors from patients 
with non-metastatic disease. In contrast, a higher expression of PD-1 was observed in tumors from patients with 
metastases compared to patients without metastases (4.5 and 0.0%, respectively, p < 0.05, Fig. 3c). A similar trend 
was observed for CD3, FOXP3, PD-L1 and PD-1 when were compared tumor samples from patients with stable 
and progressive disease (Fig. 3e–h). However, Kaplan-Meier survival analysis did not show significant differences 
in the mortality for those patients bearing tumors expressing CD3, FOXP3, PD-1 or PD-L1 (data not shown). 
These data suggest that PD-1 expression is associated with an increased malignancy in GEP-NETs but not with an 
increase in mortality rates in this cohort.
PD-1+ lymphocytes are increased in PBMCs from GEP-NET patients with progressive dis-
ease. Afterwards, the expression of PD-1 by PBMCs from patients and controls was analyzed. No signifi-
cant differences were found in the percentages or absolute numbers of CD3 + PD-1+, CD3+ CD4+ PD-1+, 
CD3+ CD8+ PD-1+ and CD3+ CD4+ CD25+ FOXP3+ PD-1+ cells (Fig. 4a–d and Supplementary Fig. S1) 
Figure 1. Representative immunohistochemical staining patterns of PD-L1 in GEP-NETs. (a–d) TMA sections 
of a G3 pancreatic NET. (a) Positive membranous staining for PD-L1 in cancer cells. (b) CD163 expression 
in peritumoral macrophages. (c) CD3 expression in peritumoral lymphocytes. (d) Negative expression of 
PD-1. (e–h) TMA sections of a G2 intestinal NET. (e) Positive membranous staining for PD-L1 in peritumoral 
infiltrating cells. (f) CD163 expression in peritumoral macrophages. (g) CD3 expression in peritumoral 
lymphocytes. (h) Positive expression of PD-1. Original magnification with 20x and 40x (insets). Scale bar 
for 100 µm is represented with a line for each panel. (i) PD-L1 expression was measured by IHC in a set of 
TMAs (n = 164) of GEP-NETs. Bar graph values represent the percentage of samples with positivity for PD-L1 
expression in the peritumoral and in tumoral tissue. (j–o) Immunofluorescence (IF) staining in a G3 intestinal 
NET. (j,m) Simple IF with PD-L1 (red). (k) Simple IF with CD68 (green). (l) Double IF with CD68 (green) and 
PD-L1 (red). (n) Simple IF with CD3 (green). (o) Double IF with CD3 (green) and PD-L1 (red). Scale bar for 
25 µm is represented with a line for each panel.
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in patients and controls. However, when patients were classified according to the phase of the disease, the levels 
of CD3 + PD-1+, CD3+ CD4+ PD-1+, and CD3+ CD4+ CD25+ FOXP3+ PD-1+ cells (Fig. 4e,f and h) were 
significantly higher in patients with progressive disease (0.47%, 0.45% and 0.22%, respectively) compared to those 
with cured (0.33%, 0.26% and 0.14%, respectively) and stable disease (0.24%, 0.17% and 0.06%, respectively). In 
contrast, patients with no residual disease had a higher expression of CD8+ PD-1+ PBMCs (0.34%) compared 
to controls (0.19%, Fig. 4g).
Simultaneous analysis of peripheral blood and tumor samples. Finally, we simultaneously analyzed 
in three patients the presence of different cell subsets in tumor infiltrating lymphocytes and PBMC samples. As 
shown in Fig. 5a–c, the proportion of CD3 + PD-1+ cells was higher in mononuclear cells isolated from tum-
ors compared to PBMC (8.97% and 2.09%, respectively). Furthermore, a significant correlation was observed 
between the percentages of CD3 + PD-1+, CD3+ CD4+ PD-1+ or CD3+ CD4+ CD25+ FOXP3+ PD-1+ 
lymphocytes in PBMCs and the level of PD-L1 expression detected by IHC in tumor tissue (p < 0.05, Fig. 5d).
Figure 2. Characterization of the immune cell infiltrate in GEP-NETs. (a–d) Serial sections of a pancreatic 
neuroendocrine tumor. (a) Intense staining for CD3 in TILs of NET tissue. (b) Staining for FOXP3 in some 
TILs. (c) Staining for PD-1 in some TILs, (d) hematoxylin-eosin staining. Original magnification with 20x 
and 40x (insets). Scale bar for 100 µm is represented with a line for each panel. (e) CD3, (f) FOXP3 and (g) 
PD-1 were measured by IHC in a set of TMAs (n = 164) of GEP-NETs, including primary and metastatic 
tissue. Values represent boxplot of CD3 IHC score and bar graphs of the percentage of samples with positivity 
for FOXP3 and PD-1 expression in the tumor tissue and in the peritumoral normal tissue. Asterisks indicate 
significant differences between tumor and peritumoral tissues (p-values for Fisher’s Exact Test: *p < 0.05). 
(h–k) Immunofluorescence showing different markers in TILs: h) Double immunofluorescence with CD3 
(green) and PD-1 (blue). (i) Double immunofluorescence with CD3 (green) and FOXP3 (red). (j) Double 
immunofluorescence with PD-1 (blue) and FOXP3 (red). (k) Triple immunofluorescence with CD3 (green), 
PD-1 (blue) and FOXP3 (red). Scale bar for 100 µm is represented with a line for each panel.
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Discussion
GEP-NETs are uncommon neoplasms that are increasingly being diagnosed. The rise in their incidence and the 
limited available therapeutic options have created an urgent demand for new treatment options. In this regard, 
cancer immunotherapy is a promising strategy in different malignant tumors. Thus, the immune checkpoint 
based therapy targeting PD-1 and PD-L1 have recently been approved for their use in patients with different 
malignant conditions, including melanoma and lung and renal cancer27, and it is very feasible that this type of 
immunotherapy could be useful in other many tumors, including GEP-NETs28. Accordingly, we decided to ana-
lyze the expression of the PD-1/PD-L1 immune checkpoint in tissue samples and peripheral blood from patients 
with GEP-NETs.
PD-L1 is expressed by a significant fraction of unstimulated conventional T cells and most Treg lympho-
cytes10. In addition, the expression of PD-L1 can be induced in B cells, monocytes and myeloid and plasmacytoid 
dendritic cells14–17. Furthermore, PD-L1 expression can be detected in other non-immune cells (for example, 
vascular endothelium), including tumor cells18. It has been described that the induction of PD-L1 expression by 
immune and non-immune cells is mainly mediated by the pro-inflammatory cytokines IFN-γ and TNF-α29–31. 
It has also been stated that PD-L1 expression by tumor cells is the best predictive marker for a good response to 
PD-1/PD-L1 blockade therapy32. In our study, only seven tumor samples (6.1%) and 8.3% of peritumoral tissue 
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No residual disease 66 (60.0%)
Stable disease 17 (15.5%)
Progressive disease 22 (20.0%)
Unknown 5 (4.6%)
Primary site
Pancreatic NET 48 (43.6%)
Gastrointestinal NET 62 (56.4%)










Somatostatin analogues 36 (32.7%)
Interferon 8 (7.3%)
Cytotoxic chemotherapy 5 (4.6%)
Sunitinib 1 (0.9%)
Everolimus 4 (3.6%)
Sample characteristics (n = 164)
Primary Tumor tissue 104 (63.4%)
Metastatic Tumor Tissue 12 (7.3%)
Non-tumor adjacent tissues 48 (29.3%)
Table 1. Patients baseline characteristics (n = 110 and sample characteristics (n = 164). Abbreviations: TNM: 
Tumor, lymph Node, Metastasis; ENETS: European Neuroendocrine Tumor Society; NET: Neuroendocrine 
Tumor; WHO: World Health Organization; G1: Grade 1; G2: Grade 2; G3: Grade 3.
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showed PD-L1 expression. In this regard, there are several controversial reports on the expression of the PD-1/
PD-L1 system in NETs and its possible association with tumor stage and disease outcome28. Thus, Fan Y et al., 
have recently reported that the survival time of patients with pulmonary NETs is significantly associated with 
PD-L1 expression by tumor cells and PD-1 expression by tumor-infiltrating lymphocytes, and that patients with 
negative PD-1/PD-L1 expression have better prognoses33. An additional report34 showed PD-L1 expression in 
only 10% of large cell neuroendocrine carcinoma and 5.8% of small cell lung cell cancer tumors, with no expres-
sion in other types of lung neuroendocrine tumors; in this study no significant association was observed between 
PD-L1 expression and overall survival. Furthermore, Schultheis AM et al., have reported a lack of expression of 
PD-1/PD-L1 by tumor cells in 94 samples of small cell lung carcinomas35. However, in this study a significant 
fraction of tumors (18.5%) showed positive staining for PD-L1 in peritumoral macrophages as well as PD-1 
expression by tumor infiltrating T lymphocytes (48% cases); the possible association between PD-L1 expression 
and disease outcome was not analyzed in this study. Moreover, Kim ST et al., detected PD-L1 expression in tumor 
tissue in 7 out of 32 GEP-NET samples analyzed (21.9%)36. In this study, those patients with PD-L1 expression 
showed a high-grade WHO classification and a diminished survival. Finally, in a very recent report of 62 small 
intestine NETs, approximately one third of samples showed PD-L1 expression in tumor cells and/or tumor infil-
trating lymphocytes TILs, with no apparent association with disease stage or patient outcome28. We consider that 
all these studies strongly indicate that the PD-1/PD-L1 immune checkpoint system is expressed in a significant 
fraction of NETs, in either tumor or immune infiltrating cells. However, the possible relationship between PD-1/
PD-L1 expression and disease outcome seems to remain as an interesting issue to be determined. In this regard, 
we consider that our data regarding the significant association between malignancy or disease progression and 
PD-L1 expression are of interest. However, It is important to note that the lack of standardization for PD-L1 
IHC in terms of the specificity and reproducibility of the available anti-PD-L1 antibodies, the different staining 
techniques (manual versus automated), the definition of PD-L1 “positive” tumor (cell surface versus cytoplasmic 
expression, by tumor cells only or by other cells in the tumor milieu, the threshold of positive cells), the interpre-
tative subjectivity, as well as including patients with different tumor grades− could be the explanation of these 
discordant results. In our study, results were different when using three different anti-PD-L1 antibodies. We used 
Figure 3. Expression of PD-1 is associated to increased malignancy in patients with GEP-NETs. (a,e) CD3,  
(b,f) FOXP3, (c,g) PD-1 and (d,h) PD-L1 were measured by IHC in a set of TMAs (n = 164) of GEP-NETs. 
Values represent boxplot of CD3 IHC score and bar graphs of the percentage of samples with positivity for 
PD-1, FOXP3 and PD-L1 expression. (a–d) Samples were classified based on metastases status at diagnosis: 
patients with metastasis (MET) or without metastasis (No MET). (e–h) Samples were classified based on the 
disease status at follow-up evaluation: (1) non-residual disease, if a complete resection after surgery had been 
achieved and no tumor relapse/recurrence was evidenced; (2) stable disease, in cases of residual but non-
progressive tumor burden; and (3) progressive disease, if tumor growth or new lesions were detected. The 
median of follow-up was 4.9 years (p25: 2.6–p75: 8.6 years). Asterisks indicate significant differences (p-value 
for Fisher’s Exact Test: *p < 0.05).
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three different antibodies against PD-L1 but only one of them stained PD-L1 in our tumor samples, probably 
because they are directed against different immunogenic domains. In any case, most of the GEP-NET patients 
that we studied did not express PD-L1 either on the tumor cells or peritumoral cells and the low percentage of 
positive tumors could be related to the reasons described above regarding IHC issues and to the low number of 
G3 tumors in our cohort37.
We also analyzed the possible presence of Treg cells expressing PD-1 in tumor or peritumoral tissue. However, 
we detected that only very few cells showed the co-expression of CD3, Foxp3 and PD-1. This unexpected finding 
suggests that, in contrast with other tumor types, Foxp3+ Treg cells do not seem to participate in the induction 
and maintenance of immune tolerance by tumor cells. However, when our patients were classified according to 
disease status, we found that the levels of circulating CD3+ CD4+ CD25+ Foxp3+ PD-1+ cells were signifi-
cantly increased in patients with progressive disease, suggesting a role of Treg lymphocytes in disease outcome. 
These results indicate that PD-1 expression in PBMCs is associated with a worse clinical outcome in GEP-NET 
patients, confirming the results that we obtained by IHC and results reported by other authors in non-small cell 
lung cancer38. Thus, we consider that the possible participation of Treg lymphocytes in GEP-NETs remains as an 
interesting a relevant issue to be elucidated.
Taken together, our results suggest that the PD-1/PD-L1 pathway, especially PD-1 expression, may exert a 
relevant pathophysiological role in GEP-NETs. Specifically, PD-1 could be involved in tumor progression and 
worsen prognosis in GEP-NET and its expression could be used to predict a patient’s response to anti-PD-1 ther-
apies. However, our results along with the controversial data reported in previous studies strongly suggest that it 
would be very convenient to perform a multicentric study to analyze a large number of cases. This type of study 
may provide very valuable information regarding the role of PD-1/PD-L1 expression in the pathophysiology of 
NETs as well as the possible involvement of Treg cells and the feasibility of immune checkpoint based therapy in 
this condition.
Figure 4. PD-1+ lymphocytes are increased in PBMCs from GEP-NET patients with progressive disease. 
PBMCs from 32 patients and 32 controls were isolated and incubated with conjugated antibodies directed 
against CD3, CD4, CD8, CD25, FOXP3 and PD-1. Measurements were made by flow cytometry as stated 
in ‘Materials and Methods’ and values represent percentage of positive cells for each marker depicted as 
boxplots. (a–d) Percentage of PD-1+ cells in healthy controls and patients. (e–h) Percentage of PD-1+ cells 
in controls and patients classified according to disease status in non-residual disease (ND), stable disease (SD) 
or progressive disease (PD). Asterisks indicate significant differences (p-values for Tukey’s test: *p < 0.05, 
**p < 0.01, ***p < 0.001).
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Materials and Methods
Individuals. A retrospective study was performed, including consecutively patients with gastrointestinal 
and pancreatic NETs with tumor samples available from 5 reference centers in Spain (Hospital Universitario 
La Princesa, Hospital Clinico Universitario, Hospital Universitario de Alcalá de Henares, Hospital Clinico San 
Carlos and Hospital Universitario Gregorio Marañón) between 1995 and 2018. A hundred and ten patients with 
GEP-NETs were studied (62 with gastrointestinal NETs and 48 with pancreatic NETs) (Table 1). All patients 
were carefully screened for the presence of other malignancies and/or genetic disorders. One patient was car-
rier of a MEN1 (Multiple Endocrine Neoplasia Type 1) gene mutation. No other apparent genetic abnormalities 
were found. Complete work-up including history, physical examination and hormone levels was performed in 
all cases and interpreted by expert endocrinologists (M.M., C.B.C., J.C.A., J.A.D., R.G.C. and M.S.N.), classifying 
all patients according to the WHO criteria (tumor site and size, angioinvasion, infiltration level, cell proliferation 
index, immunohistochemical phenotype, and metastases). According to histopathological findings, GEP-NETs 
were classified as G1, G2 or G3 (Table 1). All tumors were reviewed (tumor site and size, angioinvasion, infil-
tration level, cell proliferation index, immunohistochemical phenotype, and metastases) by expert pathologists 
(J.C.T., J.C.G.; A.I. and M.A), and the neoplasms were classified according to the WHO criteria24. GEP-NETs 
were classified as G1, G2 and G3 (Table 1). Cell proliferation activity was determined by counting the number of 
Ki-67+ cells. Thirty-two healthy age-matched subjects that had complete hormonal work-up were used as con-
trols for cell isolation and flow cytometry analyses.
Patients were managed following current recommendations and guidelines39. Elective surgery was the first 
option of treatment in all cases and adjuvant therapy with somatostatin analogues was administered if evidence 
of residual disease was observed (Table 1). According to the last follow-up evaluation (until March 2018) patients 
were classified into three categories according to their clinical status: (1) non-residual disease, if a complete resec-
tion after surgery had been achieved and no tumor relapse/recurrence was evidenced; (2) stable disease, in cases 
of residual but non-progressive tumor burden; and (3) progressive disease, if tumor growth or new lesions were 
detected. The median of follow-up was 4.9 years (p25: 2.6–p75: 8.6 years). Five patients did not have enough 
follow-up data for clinical status classification. Survival at the end of follow-up was 86% (15 patients deceased, no 
survival data in 3 patients).
Figure 5. Simultaneous analysis of peripheral blood and tumor samples. Dot plots of CD3+PD-1+ cells from 
(a) peripheral blood and (b) tumor specimen from a representative GEP-NET patient. (c) Paired analysis 
of expression of CD3 + PD-1+ cells in PBMCs and TILs from 3 patients with GEP-NETs. Values represent 
percentage of CD3 + PD-1+ cells in PBMCs and TILs. P-value from paired T test is shown. (d) Correlation 
map for the expression of immune markers in TMAs (IHC) and PBMCs (flow cytometry). Values represent 
the Spearman’s rank correlation coefficient, rho (ρ). Significant negative correlations are shown in orange and 
significant positive correlations in blue. Color intensity increases with the magnitude of correlation. White color 
indicates a non-significant correlation.
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This project was approved by the Internal Ethical Review Committee of the Hospital de La Princesa, and 
written informed consent was obtained from all patients prior to inclusion, in accordance with the Declaration 
of Helsinki.
Tissue samples. A total of 164 formalin-fixed paraffin-embedded tissues were evaluated by using a tissue 
microarray (TMA). Of these, 116 were proper tumor samples with pathological diagnosis and 48 corresponded 
to peritumoral tissue regions. All samples were taken and managed in accordance with regulations and approval 
of the local Institutional Review Board.
Immunohistochemistry (IHC). Tissue sections were dewaxed, rehydrated and washed in phosphate buff-
ered saline 1x (PBS; Lonza, Verviers, Belgium). Epitope retrieval was performed by treating the slides in a PT Link 
(Dako, Agilent Technologies, Santa Clara, CA, United States) containing an acid or basic solution (as appropri-
ate), preheated to 97 °C, for 30 minutes. Next, endogenous peroxidase was inhibited with a peroxidase-blocking 
solution (Dako, Agilent Technologies, Santa Clara, CA, United States) for 5 minutes. Afterwards, sections 
were immunostained with the following primary antibodies: anti-CD3 (polyclonal, ref.: A0452, Dako, Agilent 
Technologies, Santa Clara, CA, United States), anti-PD-L1 with three different antibodies (clone SP142, Ventana 
Medical Systems, Roche, Tucson, Arizona, USA; clone 28-8 and clone 22C3, Dako, Agilent Technologies, Santa 
Clara, CA, United States), anti-PD-1 (clone NAT105, Ventana Medical Systems, Roche, Tucson, Arizona, USA), 
anti-FOXP3 (clone 236 A/E7, Abcam, Cambridge, UK) and anti-Ki-67 (clone MIB-1, Dako, Agilent Technologies, 
Santa Clara, CA, United States). Next, sections were incubated with the proper horseradish peroxidase-conjugated 
secondary antibodies: goat anti-mouse, goat anti-rabbit or rabbit anti-goat (Ref: P0447, P0448 P0449, respec-
tively, Dako, Agilent Technologies, Santa Clara, CA, United States). Finally, sections were incubated with 
3,3′-diaminobenzidine (DAB; Dako, Agilent Technologies, Santa Clara, CA, United States), counterstained with 
hematoxylin (Sigma-Aldrich, St Louis, MO, USA), dehydrated in alcohol, cleared with xylene and mounted. For 
each section, the approximate percentage of positive cells (proportion score, PS) and staining intensity (intensity 
score, IS) determined the CD3 staining score (CD3 IHC score). Five different high-power fields at the hot-spot 
areas of each slide were observed in a blinded manner. The proportion of stained cells in each field were assessed 
as follows: 1 for 5% stained cells; 2 for 6–25% stained cells; 3 for 26–50% stained cells; and 4 for >50% stained 
cells. Intensity of overall staining was graded as follows: 0 for negative staining; 1 for light staining; 2 for moderate 
staining; and 3 for intense staining. The total staining score (TS) for one field was obtained by adding the score of 
the proportion of stained cells with the score of the staining intensity (TS = PS + IS). The final TS was the mean 
of the 5 fields. For the rest of markers in tumor cells and in tumor infiltrating lymphocytes (TILs), sections were 
scored at 5% intervals, and patients with >5% staining were considered positive for that marker. Tonsil tissue 
served as positive control for the different antibodies.
Immunofluorescence. Tissue sections were dewaxed, rehydrated and washed in PBS 1x (Lonza, Verviers, 
Belgium). Epitope retrieval was performed by treating the slides in a PT Link (Dako, Agilent Technologies, Santa 
Clara, CA, United States) as described above for IHC. Next, sections were incubated for 1 hour with a block-
ing solution consisting of 2% (w/v) bovine serum albumin (BSA, Roche, Tucson, Arizona, USA) and 10% (v/v) 
human serum (Sigma-Aldrich, St Louis, MO, USA) diluted in PBS 1x. Then, sections were incubated at 4 °C over-
night with the following primary antibodies: anti-CD3 (Ref: A0452, Dako, Agilent Technologies, Santa Clara, CA, 
United States), anti-PD-1 (Ref: AF1086, R&D Systems, Minneapolis, MN), anti-FOXP3 (Ref: ab20034, Abcam, 
Cambridge, UK), anti-CD3 (Ref: M7254, Dako, Agilent Technologies, Santa Clara, CA, United States), anti-CD68 
(Ref. M0876, Dako, Agilent Technologies, Santa Clara, CA, United States) and anti-PDL1 (SP263, Cat. 790–4905, 
Roche, Tucson, Arizona, USA). The next day tissue samples were washed with PBS 1x (3 times, 5 minutes each). 
Afterwards, tissue sections were incubated for 30 minutes with 4′,6-Diamidino-2-Phenylindole (DAPI, Thermo 
Fisher Scientific, Waltham, MA, USA) and the appropriate secondary antibodies labeled with a fluorophore: don-
key anti-goat Alexa Fluor® 488, donkey anti-rabbit Alexa Fluor® 647, donkey anti-mouse Alexa Fluor® 555, goat 
anti-mouse Alexa Fluor® 488, and goat anti-rabbit Alexa Fluor® 568 (Cat. A-11055, A-31573, A-31570, A-32723, 
A-11036 respectively, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Finally, sections were washed 
with PBS 1x (3 times, 5 minutes each), mounted and analyzed with a Leica TCS-SP5 confocal microscope (Leica 
Microsystems, Wetzlar, Germany).
Cell isolation. Peripheral blood samples were obtained from 32 patients and 32 healthy controls. Peripheral 
blood mononuclear cells (PBMCs) were isolated by Biocoll separating solution (Merck, Berlin, Germany)) 
density-gradient centrifugation. Cellular viability was assessed by trypan blue dye exclusion and it was always 
higher than 95%. GEP-NET TILs were isolated from 3 surgical specimens. Briefly, tumor tissue was minced and 
digested with collagenase (1.0 mg/ml; Roche, Tucson, Arizona, USA) for 1 hour at 37 °C and 5% CO2. Then, cells 
were passed through a steel mesh (BD Biosciences, San Jose, CA, USA) and mononuclear cells were isolated by 
Biocoll separating solutiondensity-gradient centrifugation. Afterwards, TILs were washed and resuspended in 
RPMI 1640 with GlutaMAX culture medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% (v/v) fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), penicillin (50 IU/ml) and strepto-
mycin (50 µg/ml) (Sigma-Aldrich, St Louis, MO, USA).
Flow cytometry analysis (Fluorescence-activated cell sorting, FACS). Cell surface expression was 
assessed on freshly isolated TILs or PBMCs by staining with the following monoclonal antibodies: CD3-Pacific 
Orange (Clone UCHT1, Cat. 561416, BD Biosciences, San Jose, CA, USA), CD4-APC-Cy7 (Clone OKT4, Cat. 
317418, Biolegend, San Diego, CA), CD8-FITC (Clone RPA-T8, Cat. 555366, BD Biosciences, San Jose, CA, 
USA), CD25-Phycoerythrin (Clone M-A251, Cat. 555432, BD Biosciences, San Jose, CA, USA) and PD-1-Pacific 
Blue (Clone EH12.2H7, Cat. 329916, Biolegend, San Diego, CA). For detection of intracellular expression of 
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FOXP3, cells were permeabilized and fixed with the ‘FOXP3 Staining Buffer Set’ (BD Biosciences, San Jose, CA, 
USA) following the manufacturer’s instructions, and then they were incubated with the anti-FOXP3-PE-Cy7 
monoclonal antibody (Clone PCH101, Ref: 25-4776-42, BD Biosciences, San Jose, CA, USA). Cell analysis was 
performed with a FACSCanto flow cytometer (BD Biosciences, San Jose, CA, USA).
Statistical analysis. Data are shown as the median and interquartile range (boxplots) for quantitative vari-
ables and as relative percentages of samples (bar graphs) for qualitative variables included in contingency tables. 
Fisher’s exact test was used for qualitative variables comparisons. The unpaired two-tailed Student t-test was 
used to compare two independent groups and the paired Student t-test to analyze two related samples. One-way 
ANOVA was used to compare more than two groups and post-hoc multiple comparisons were done with Tukey’s 
test (follow-up losses were not included in clinical status comparison). Furthermore, survival data was analyzed 
by Kaplan-Meier method. Spearman’s rho analyses were performed to find correlations between blood markers 
and immune markers studied by IHC. Analyses were performed using Stata v. 12.0 for Windows and R version 
3.3.2. Package ggplots240 and corrplot41 were used for graphics. For statistical significance, p-values smaller than 
0.05 were considered statistically significant.
References
 1. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14, 
1014–1022, https://doi.org/10.1038/ni.2703 (2013).
 2. Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin 
Oncol 39, 98–106, https://doi.org/10.1097/COC.0000000000000239 (2016).
 3. Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25, 9543–9553, https://
doi.org/10.1128/MCB.25.21.9543-9553.2005 (2005).
 4. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. 
Cancer Cell 27, 450–461, https://doi.org/10.1016/j.ccell.2015.03.001 (2015).
 5. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical 
activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28, 3167–3175, https://doi.org/10.1200/JCO.2009.26.7609 
(2010).
 6. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving 
nivolumab. J Clin Oncol 32, 1020–1030, https://doi.org/10.1200/JCO.2013.53.0105 (2014).
 7. McDermott, D. F. et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell 
Carcinoma Receiving Nivolumab. J Clin Oncol 33, 2013–2020, https://doi.org/10.1200/JCO.2014.58.1041 (2015).
 8. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562, 
https://doi.org/10.1038/nature13904 (2014).
 9. Nowicki, T. S., Hu-Lieskovan, S. & Ribas, A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J 24, 47–53, https://
doi.org/10.1097/PPO.0000000000000303 (2018).
 10. Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236, 219–242, https://
doi.org/10.1111/j.1600-065X.2010.00923.x (2010).
 11. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 
677–704, https://doi.org/10.1146/annurev.immunol.26.021607.090331 (2008).
 12. Liang, S. C. et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33, 
2706–2716, https://doi.org/10.1002/eji.200324228 (2003).
 13. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2, 261–268, https://doi.
org/10.1038/85330 (2001).
 14. Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease 
progression through PD-L1. J Exp Med 206, 1327–1337, https://doi.org/10.1084/jem.20082173 (2009).
 15. Wu, K., Kryczek, I., Chen, L., Zou, W. & Welling, T. H. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma 
is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69, 8067–8075, https://doi.org/10.1158/0008-5472.CAN-09-
0901 (2009).
 16. Perrot, I. et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 178, 
2763–2769, https://doi.org/10.4049/jimmunol.178.5.2763 (2007).
 17. Khan, A. R. et al. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 6, 5997, https://doi.org/10.1038/
ncomms6997 (2015).
 18. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8, 467–477, https://doi.
org/10.1038/nri2326 (2008).
 19. Ostrand-Rosenberg, S., Horn, L. A. & Haile, S. T. The programmed death-1 immune-suppressive pathway: barrier to antitumor 
immunity. J Immunol 193, 3835–3841, https://doi.org/10.4049/jimmunol.1401572 (2014).
 20. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206, 
3015–3029, https://doi.org/10.1084/jem.20090847 (2009).
 21. Intlekofer, A. M. & Thompson, C. B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J 
Leukoc Biol 94, 25–39, https://doi.org/10.1189/jlb.1212621 (2013).
 22. Lee, Y. H., Bae, S. C., Kim, J. H. & Song, G. G. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations 
with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol 74, 230–239, https://doi.
org/10.1007/s00393-014-1415-y (2015).
 23. Gao, J. et al. Meta-analysis of programmed cell death 1 polymorphisms with systemic lupus erythematosus risk. Oncotarget 8, 
36885–36897, https://doi.org/10.18632/oncotarget.16378 (2017).
 24. Chai, S. M., Brown, I. S. & Kumarasinghe, M. P. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and 
molecular updates. Histopathology 72, 153–167, https://doi.org/10.1111/his.13367 (2018).
 25. Kos-Kudla, B. et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of 
lanreotide. Contemp Oncol (Pozn) 21, 115–122, https://doi.org/10.5114/wo.2017.68619 (2017).
 26. Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 
cases in the United States. J Clin Oncol 26, 3063–3072, https://doi.org/10.1200/JCO.2007.15.4377 (2008).
 27. Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: 
a comprehensive review of registration trials and future considerations. J Immunother Cancer 6, 8, https://doi.org/10.1186/s40425-
018-0316-z (2018).
 28. Lamarca, A. et al. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 9, 14922–14938, 
https://doi.org/10.18632/oncotarget.24464 (2018).
www.nature.com/scientificreports/
1 1SCIEntIfIC REpoRTs |         (2018) 8:17812  | DOI:10.1038/s41598-018-36129-1
 29. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and 
interleukin-10 secretion. Nat Med 5, 1365–1369, https://doi.org/10.1038/70932 (1999).
 30. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8, 793–800, 
https://doi.org/10.1038/nm730 (2002).
 31. Yamazaki, T. et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169, 5538–5545, https://doi.
org/10.4049/jimmunol.169.10.5538 (2002).
 32. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to 
anti-PD-1 therapy. Clin Cancer Res 20, 5064–5074, https://doi.org/10.1158/1078-0432.CCR-13-3271 (2014).
 33. Fan, Y. et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9, 6075–6082, 
https://doi.org/10.2147/OTT.S115054 (2016).
 34. Tsuruoka, K. et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer 108, 115–120, https://doi.org/10.1016/j.
lungcan.2017.03.006 (2017).
 35. Schultheis, A. M. et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51, 421–426, https://doi.
org/10.1016/j.ejca.2014.12.006 (2015).
 36. Kim, S. T. et al. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer 7, 484–489, https://doi.org/10.7150/
jca.13711 (2016).
 37. Cavalcanti, E., Armentano, R., Valentini, A. M., Chieppa, M. & Caruso, M. L. Role of PD-L1 expression as a biomarker for GEP 
neuroendocrine neoplasm grading. Cell Death Dis 8, e3004, https://doi.org/10.1038/cddis.2017.401 (2017).
 38. Zheng, H. et al. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell 
lung cancer. Oncotarget 7, 56233–56240, https://doi.org/10.18632/oncotarget.9316 (2016).
 39. Oberg, K. et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. 
Neuroendocrinology 105, 201–211, https://doi.org/10.1159/000472254 (2017).
 40. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2009).
 41. Taiyun, W. V. S. R package “corrplot”: Visualization of a Correlation Matrix, https://github.com/taiyun/corrplot (2017).
Acknowledgements
We thank Francisca Molina-Jimenez from the Instituto Universitario Princesa for kindly giving technical 
assistance with confocal microscopy. We also warmly thank all the participants included in the study for their 
selfless participation. We also thank the Centro de Investigación Biomédica en Red de Enfermedades Raras 
(CIBERER GCV14/ER/12) for their support. This work was supported by the following grants: Proyectos 
de Investigación en Salud (FIS) PIE13-0041 and PI16-02091 (funded by Instituto de Salud Carlos III), 
TIRONET2-CM, B2017/BMD-3724 (funded by Comunidad de Madrid), GETNE G1707 (funded by Grupo 
Español de Tumores Neuroendocrinos y Endocrinos) to M.M. Proyectos de Investigación en Salud (FIS) 
PI15/01501-FEDER (funded by Instituto de Salud Carlos III) to J.C.T.
Author Contributions
Conception of the work: M.S.N., M.M. Design of research: M.S.N., J.C.T., R.G.A., M.M. Performed experiments: 
M.S.N., A.S.S., M.A., R.M.H., J.C.T., J.C.G., A.I., M.M. Data analysis: M.S.N., A.S.S., M.M. Interpreted results 
of experiments: M.S.N., A.S.S., M.A., J.C.T., R.M.H., J.C.G., A.I., R.G.A., M.M. Prepared figures: M.S.N., A.S.S., 
M.M. Acquisition of clinical data and samples: M.S.N., C.B.C., E.M.P., J.M.N., J.A.D., R.G.C., M.M. Draft the 
work: M.S.N., A.S.S., J.C.T., R.G.A., M.M. Wrote the manuscript M.S.N., A.S.S., J.C.T., R.G.A., M.M. Critically 
revised the manuscript for important intellectual content and approved final version of manuscript, M.S.N., 
A.S.S., M.A., J.C.T., C.B.C., J.C.A., R.M.H., E.M.P., J.M.N., J.A.D., R.G.C., J.C.G., A.I., R.G.A., M.M.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-36129-1.
Competing Interests: M.M. and M.S.N. has received speaker’s fees from Novartis and Ipsen. The rest of the 
authors have nothing to disclose.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
